Arcutis Biotherapeutics had its Relative Strength (RS) Rating upgraded from 87 to 91 Thursday.
This proprietary rating tracks market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the trailing 52 weeks matches up against all other stocks in our database.
Decades of market research reveals that the market's biggest winners often have an RS Rating of above 80 in the early stages of their moves.
How To Use Stock Charts To Stay Profitable And Protected
Arcutis Biotherapeutics is building a consolidation with a 16.20 buy point. See if it can break out in heavy trade.
The company reported 0% earnings growth last quarter. Revenue gains came in at 427%.
Arcutis Biotherapeutics holds the No. 32 rank among its peers in the Medical-Biomed/Biotech industry group. GeneDx Holdings, Exelixis and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
